One of the largest merger announcements in India’s healthcare sector has moved closer to completion. The proposed merger between Aster DM Healthcare Limited and Quality Care India Ltd (QCIL) has received an order from the Hon’ble National Company Law Tribunal (NCLT), Hyderabad Bench, directing the convening of meetings of shareholders and unsecured trade creditors to seek approval for the transaction.
The meetings are scheduled to be held on a date between 27 February 2026 and 13 March 2026, marking a critical milestone in the merger process.
Key Regulatory Approvals Already in Place
Notably, the merger has already secured approval from the Competition Commission of India (CCI). In addition, both companies have received ‘No Objection’ letters from the Stock Exchanges, significantly strengthening regulatory certainty.
Subject to the receipt of remaining statutory approvals and fulfilment of other customary conditions precedent, the companies expect to complete the merger by Q1 of FY 2026–27.
Formation of Aster DM Quality Care Limited
Upon completion, the merged entity—Aster DM Quality Care Limited—will be promoted by Aster Promoters and Blackstone. The transaction brings together two leading healthcare providers with a shared vision of expanding access to high-quality medical care across India.
By combining complementary networks, clinical expertise, and operational capabilities, the merger aims to create a stronger and more resilient healthcare platform.
Leadership Perspective on Strategic Integration
Commenting on the progress, Dr Azad Moopen, Founder & Chairman, Aster DM Healthcare, said,
“We are pleased with the significant progress achieved in the merger process and are confident of receiving shareholders’ and unsecured creditors’ approval pursuant to the NCLT order. We remain committed to completing the merger expeditiously and look forward to making it effective by Q1 FY 2026–27.”
He further added, “Going forward, our focus will be on executing a disciplined integration strategy that leverages the complementary networks, clinical expertise, and operational strengths of Aster and Quality Care. This merger provides a strong platform to scale efficiently, enhance clinical excellence, and accelerate innovation—allowing us to build a future-ready healthcare organisation that improves access and patient outcomes across the country.”
Expanded Portfolio of Leading Healthcare Brands
As per the press release, the merged entity will operate a diversified portfolio of four established healthcare brands: Aster DM, CARE Hospitals, KIMSHEALTH, and Evercare. As of 30 September 2025, the combined bed strength of Aster and QCIL exceeded 10,360 beds, with Aster contributing 5,195+ beds and QCIL contributing 5,165+ beds.
Growth Plans and Future Opportunities
Looking ahead, Aster DM Quality Care Limited plans to expand its bed capacity to approximately 14,715+ beds over the coming years. With enhanced scale and financial strength, the merged entity will also be well positioned to invest in advanced medical technologies and digital health platforms.
Consequently, the merger is expected to drive innovation, improve operational efficiencies, and create a more integrated and seamless patient experience—reinforcing the group’s long-term commitment to accessible, high-quality healthcare across India.